Curaleaf Holdings initiated a hostile takeover attempt of Canadian licensed producer Aurora Cannabis on August 18, circumventing Aurora's board of directors to present the acquisition proposal directly to shareholders.
The Massachusetts-based multi-state operator filed the formal tender offer with securities regulators, marking an escalation in what had been private negotiations between the two publicly traded cannabis companies. Aurora's leadership has not publicly endorsed the bid.
Curaleaf's move represents one of the most aggressive cross-border acquisition attempts in the North American cannabis sector since federal legalization in Canada. The MSO operates 150 retail locations across 18 U.S. states and reported $1.4 billion in revenue for fiscal 2023.
The Deal Structure
Details of Curaleaf's valuation and proposed share exchange ratio were not disclosed in initial regulatory filings. The hostile tender offer gives Aurora shareholders a set period—typically 30 to 60 days—to decide whether to tender their shares directly to Curaleaf.
Aurora Cannabis trades on the Toronto Stock Exchange and Nasdaq. The Edmonton-based company has struggled with profitability despite being one of Canada's largest licensed producers by cultivation capacity. Aurora reported a net loss of $141 million in its most recent fiscal year.
The acquisition would give Curaleaf access to Aurora's international medical cannabis distribution network, which spans 25 countries. But the deal faces regulatory hurdles. U.S. federal cannabis prohibition means Curaleaf cannot legally import Canadian product into American markets where it operates dispensaries.
Industry Consolidation
The hostile bid comes as cannabis companies on both sides of the border face margin pressure and oversupply. Canadian LPs have seen share prices decline 70% or more from 2019 peaks. Several major producers have shuttered cultivation facilities or filed for creditor protection.
Curaleaf has pursued growth through acquisition before. The company bought Grassroots in 2020 for $875 million and acquired European medical cannabis distributor EMMAC Life Sciences in 2021. But this marks its first unsolicited takeover attempt.
"Cross-border M&A in cannabis is complicated by federal illegality in the U.S.," said one Toronto-based cannabis investment analyst who requested anonymity. "Curaleaf would need to operate Aurora as a separate entity, which raises questions about synergies."
What Happens Next
Aurora's board will likely issue a formal response within two weeks, either endorsing the offer, rejecting it, or presenting an alternative transaction. The company could also seek a white knight bidder or implement a poison pill defense.
Shareholders of record as of the offer date will receive tender materials by mail. Canadian securities law requires a minimum 35-day tender period for hostile bids.
Curaleaf must secure approval from the Canadian Investment Review Board, which scrutinizes foreign acquisitions of Canadian companies. The deal would also require clearance from the Toronto Stock Exchange and potentially the Nasdaq if share exchanges are involved.
Aurora's institutional shareholders—including ETF Managers Group and AdvisorShares—collectively hold approximately 40% of outstanding shares. Their decision to tender or hold will likely determine whether Curaleaf's hostile bid succeeds.
This article is based on original reporting by mjbizdaily.com.
